Radioterapi pada Sarkoma Uterus

Yoseph Adi Kristian, Sri Mutya Sekarutami

Sari


Sarkoma uterus merupakan keganasan uterus yang langka. Secara umum tumor ini dianggap memiliki karakter yang agresif dan sering dikaitkan dengan prognosis yang buruk. Walaupun penggunaan radioterapi masih diperdebatkan, terdapat penelitian yang menunjukkan  bahwa radioterapi adjuvan dapat memperbaiki local-regional failure free survival (LRFFS) 5 tahun dari 55.3% menjadi 70.8% serta secara signifikan mampu meningkatkan survival rate.

 


Kata Kunci


Sarkoma Uteri, karsinosarkoma, radioterapi

Teks Lengkap:

PDF

Referensi


Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012. v1.0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr. Accessed 20 Dec 2017.

American Cancer Society: Cancer Facts and Figures 2013. Atlanta: American Cancer Society; 2014.

Rajaram S, Gupta M. Uterine sarcomas: risk factors, clinical presentation, diagnosis, and staging. Springer. 2015;339-41.

Abeler VM, Thoresen S, Danielsen HE, Nesland JM, et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2013;54:355–64.

Trop CG, Abeler MV. Diagnosis and treatment of sarcoma of the uterus: A review. Acta Oncol. 2013;51: 694–705.

Brooks SE, Zhan M, Cote T, Baquet CR. Surveillance, epidemiology, and end results analysis of 2677 cases of uterine sarcoma 1989–1999. Gynecol Oncol. 2014;93:204–8.

Helman LJ, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 3. 2003;685-694.

Hiroshi K, Chiaki U, Juria A, et al. The biology of uterine sarcomas: A review and update. Mol Clin Oncol. 2013;1:599–609.

Lee C, Ou W, Marino A, et al. 14-3-3 fusion oncogenes in high grade endometrial stromal sarcoma. PNAS. 2012;109:929–34.

Hayashi T, Kobayashi Y, Kohsaka S, Sano K. The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2. Oncogene. 2006;25:4016–26.

Jaakkola S, Lyytinen HK, Pukkala E, et al. Use of estradiol-progestin therapy associates with increased risk for uterine sarcomas. Gynecol Oncol. 2011;122: 260–3.

Hoogendoorern WE, Hollema H, Van Boven HH, et al. Prognosis of uterine corpus cancer after tamoxifen treatment for breast cancer. Breast Cancer Res Treat. 2008;112:99–108.

Nilbert M, Therkildsen C, Nissen A, et al. Sarcomas associated with hereditary nonpolyposis colorectal cancer: Broad anatomical and morphological spectrum. Fam Cancer. 2009;8:209–13.

D’ Angelo E, Prat J. Uterine sarcomas: A review. Gynecol Oncol. 2015;131–9.

Shah SH, Jagannathan JP, Krajewski K, O’Regan KN, et al. Uterine sarcomas: Then and now. Am J Roentgenol. 2012;199:213–23.

Sandberg AA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: leiomyosarcoma. Cancer Genet Cytogenet. 2005;161:1–19.

Bansal N, Herzog TJ, Burke W, Cohen CJ, Wright JD. The utility of preoperative endometrial sampling for the detection of endometrial sarcomas. Gynecol Oncol. 2008;110:43–8.

Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A gynecologic oncology group study of cancer 2013;71: 1702–1709.

Cherian RS. Magnetic resonance imaging in endometrial cancer. Springer 2015;81-88.

Rha S, Byun J, Jung S, et al. CT and MRI of uterine sarcomas and their mimickers. AJR Am J Roentgenol. 2003;181:1369–74.

American Joint Committee on Cancer Manual Eight Edition. Springer 2017.

Maheswari A. Surgical management of uterine sarcoma. Springer 2015;351-60.

Galaal K, Kew FM, Tam KF, et al. Evaluation of prognostic factors and treatment outcomes in uterine carcinosarcoma. Eur J Obstet Gynecol Reprod Biol. 2009;143:88–92.

Park JY, Kim DY, Kim JH, et al. The role of pelvic and/or para-aortic lymphadenectomy in surgical management of apparently early carcinosarcoma of uterus. Ann Surg Oncol. 2010;17:861–8.

Hou HL, Meng MB, Chen XL, et al. The prognosis factor of adjuvant radiation therapy after surgery in uterine sarcomas. OncoTargets and therapy. 2015;8:2339-44.

Wong P, Han K, Sykes J, Catton C, Laframboise S, Fyles A, Manchul L, Levin W, Milosevic M. Postoperative radiotherapy improves local control and survival in patient with uterine leiomysocarcoma. Radiation Oncology. 2013; 8:128.

Sagus S, David KG. Role of radiation therapy in uterine sarcoma. Best Practice & Research Clinical Obstetric and Gynecology.2011;25:761-72.

Sorbe B, Paulsson G, Andersson S, Steineck G. A population-based series of uterine carcinosarcomas with long-term follow-up. Acta Oncol. 2013;52(4):759–66.

Giuntoli RL, Metzinger DS, Dimarco CS, et al. Retrospective review of 208 patients with leiomyosarcoma of the uterus: Prognostic indicators, surgical management, and adjuvant therapy. Gynecol Oncol. 2012;89:460–9.

Reed NS, Mangioni C, Malmström H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: An European organization for research and treatment of cancer gynaecological cancer group study (protocol 55874). Eur J Cancer. 2008; 44(6):808–18.

Gadducci A, Sartori E, Landoni F, et al. Endometrial stromal sarcoma: Analysis of treatment failures and survival. Gynecol Oncol. 1996;63:247–53.

Sampath S, Schultheiss TE, Ryu JK, et al. The role of adjuvant radiation in uterine sarcomas. Int J Radiat Oncol Biol Phys. 2010;76:728–34.

Leath CA, Huh WK, Hyde J, Cohn DE, et al. A multi-institutional review of outcomes of endometrial stromal sarcoma. Gynecol Oncol. 2007;105(3):630–4.

NCCN guidelines version 1. 2018. Uterine Sarcoma

Beyzadeoglu M, Ebruli C, Ozyigit G. Gynecological cancers. In: Beyzadeoglu M, Ebruli C, Ozyigit G (ed). Basic Radiation Oncology. Berlin: Springer Verlag; 2010. p. 447-

Annede P, Gouy S, Mazeron R, et al. Optimizing local control in high‐grade uterine sarcoma: Adjuvant vaginal vault brachytherapy as part of a multimodal treatment. The Oncologist. 2017;22(2):182-188.

Otto K. Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys. 2008;35:310-17.

Cozzi L, Dinshaw KA, Shrivastava SK, et al. A treatment planning study comparing volumetric arc modulation with RapidArc and fixed field IMRT for cervix uteri radiotherapy. Radiother Oncol. 2008;89:180-91.

Gadducci, Angiolo C, Stefania R, Antonella G, et al. The management of patients with uterine sarcoma: A debated clinical challenge. Critical reviews in oncology/hematology. 2008;129-42.

Odunsi K, Moneke V, Tammela J, et al. Efficacy of adjuvant CYVADIC chemotherapy in early-stage uterine sarcomas: Results of long-term follow-up. Int J Gynecol Cancer 2004;14:659–64.

Resnik E, Chambers SK, Carcangiu ML, Kohorn EI, et al. A phase II study of etoposide, cisplatin, and doxorubicin chemotherapy in mixed mullerian tumors of the uterus. Gynecol Oncol 1995;56:370–5.




DOI: https://doi.org/10.32532/jori.v9i1.72 <

Article metrics

Abstract views : 202 | views : 809

Refbacks

  • Saat ini tidak ada refbacks.




  

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.